Compound Library
Evidence-based research summaries across 9 categories.
Dual GIP/GLP-1 receptor agonist extensively studied in SURMOUNT and SURPASS trials for metabolic health and weight management research.
Triple agonist (GIP/GLP-1/Glucagon) under phase 2/3 investigation. Early trials show remarkable metabolic and weight-reduction signals.
Highly studied GLP-1 receptor agonist. STEP and SUSTAIN trial programs constitute some of the largest peptide clinical trial bodies in history.
GLP-1/Glucagon dual agonist under active phase 2/3 investigation for metabolic and NASH research.
Fragment of HGH (amino acids 176-191) studied specifically for lipolytic activity without the growth-promoting effects of full HGH.
Small molecule NNMT inhibitor studied for its potential in obesity and metabolic disease research contexts.
First-generation GLP-1 receptor agonist (Victoza/Saxenda). Once-daily injectable studied extensively for T2D glycemic control and obesity. Foundational molecule in the GLP-1 research class.
Oral non-peptide small molecule GLP-1 receptor agonist. First-in-class daily pill format studied as an alternative to injectable GLP-1 therapies. Phase 3 trials underway (Eli Lilly).
Twice-daily oral small molecule GLP-1 receptor agonist (Pfizer). Studied as pill-format GLP-1 alternative. Phase 3 program paused 2024 due to GI tolerability; research continues on modified release formulations.
Next-generation triple receptor agonist research class (GLP-1 + GIP + glucagon). Represents the frontier beyond tirzepatide dual agonism. Several candidates in research including LY3305677 and CT-996.